Peptide users describe migraines, eye pain and fatigue
Some users of unproven gray-market peptides, including BPC-157, report migraines, eye pain and fatigue. Their side effects are described as agonizing, even as the drugs grow more popular as supplements.
By Standard Topic. AI-generated from the reporting listed under Coverage. Published . Updated .
This story is no longer being updated. It reflects reporting up to .
What happened
Some people who have used experimental peptides such as BPC-157 describe migraines, eye pain and fatigue. Gray-market research peptides are becoming more popular as medical supplements, and some users say the side effects are agonizing.
Why it matters
The drugs are popular despite being unproven, and users say the side effects can be agonizing.
Timeline
- Oct 13, 5:00 AM ET: Accounts emerge of migraines, eye pain and fatigue among people who took experimental peptides.
- Oct 14, 4:00 PM ET: Users of gray-market peptides describe bizarre medical issues tied to the products.
Coverage
- People Taking Gray Market Peptides Say They're Causing Bizarre Medical Issues (futurism.com)
- People Say These Peptides Hurt Them. Their Stories Are Muffled in MAHA’s Push for Medical Freedom. (kffhealthnews.org)
More from Health
- Hackensack Meridian Health and Hunterdon Health agree to merge
- Roche signs $15 billion antibody-drug conjugate deal with Hansoh
- Putin's daughter predicts aging breakthroughs within 10 to 20 years
- Cardiologists urged to prescribe exercise for heart patients
- Pennsylvania measles outbreak tops 1,200 as CDC sends investigator
- AstraZeneca enlists Oracle to apply AI in drug trials